Mode
Text Size
Log in / Sign up
N/A N=12 Randomized Triple-blind Treatment

Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability

Fatigue · Aging

Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Dec 2015
Primary outcome: Primary: Change in Muscle Fatigue After 1 Week of Placebo or Sildenafil — 107; 115; 54; 158 percent change of successful repetitions — p=0.02

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Placebo sildenafil (Drug); Sildenafil (Drug)
Age
Adult, Older Adult · 20+ yrs
Sex
Male
Sponsor
The University of Texas Medical Branch, Galveston
Primary completion
Jul 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Muscle Fatigue After 1 Week of Placebo or Sildenafil
107; 115; 54; 158 0.02 sig
SECONDARY
Protein Synthesis Rate After 1 Week of Sildenafil or Placebo
0.06; 0.11; 0.04; 0.10 0.004 sig

Summary

This is a pilot study funded by the National Institutes of Health. In this project, we will investigate the potential effect of skeletal muscle nitric oxide (NO) production on muscle strength and physical function in older individuals. We propose to test a new method that may enable simultaneous determination of both vascular and skeletal muscle NO production for the first time in humans. Further, we will determine whether augmentation of NO-mediated responses, by administration of sildenafil citrate (Viagra), reduces fatigue and fatigability in older individuals.

Eligibility Criteria

Inclusion Criteria

  • 1. Age 20-35 yrs, and 60-80 yrs.
  • 2. Ability to sign consent form (score >23 on the 30-item Mini Mental State Examination, MMSE)
  • 3. Stable body weight for at least 3 months

Exclusion Criteria

  • 1. Physical dependence or frailty (impairment in any of the Activities of Daily Living (ADL), history of falls (>2/year) or significant weight loss in the past year)
  • 2. Exercise training (>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)
  • 3. Pregnancy
  • 4. Significant heart, liver, kidney, blood or respiratory disease
  • 5. Peripheral vascular disease
  • 6. Diabetes mellitus or other untreated endocrine disease
  • 7. Active cancer
  • 8. Use of nitrates
  • 9. Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.
  • 10. Alcohol or drug abuse
  • 11. Severe depression (>5 on the 15-item Geriatric Depression Scale, GDS)
  • 12. Cardiac abnormalities such as a cardiac shunt or previously diagnosed pulmonary hypertension.
  • 13. Systolic blood pressure 150, diastolic blood pressure 90.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01059994). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search